DOI: 10.1055/s-00035024

Thrombosis and Haemostasis

Issue 02 · Volume 124 · February 2024 DOI: 10.1055/s-014-58948

Coagulation and Fibrinolysis

  • 089
    Duarte-Gamas, Luís; Jácome, Filipa; Dias, Lara Romana; Rocha-Neves, João; Yeung, Kak K.; Baekgaard, Niels; Dias-Neto, Marina:

    Catheter-Directed Thrombolysis Protocols for Deep Venous Thrombosis of the Lower Extremities—A Systematic Review and Meta-analysis

    Image for article: Catheter-Directed Thrombolysis Protocols for Deep Venous Thrombosis of the Lower Extremities—A Systematic Review and Meta-analysis
    Supplementary Material (PDF)

    • Invited Editorial Focus

  • 105
    Barnes, Geoffrey D.; Obi, Andrea T.:

    Catheter-Directed Thrombolysis for Deep Vein Thrombosis: Serving at Break Point

    • Coagulation and Fibrinolysis

  • 108
    Yu, Jinchao; Wang, Tianfa; Zhang, Xiaohan; Chen, Qing; Hu, Yajun; Liang, Qiaoyan; Shi, Yun; Wang, Yuxiong; Zhang, Yanling; Yu, Min; Zhao, Bing:

    Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

    Image for article: Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding
    Supplementary Material (PDF)

    • Cellular Haemostasis and Platelets

  • 122
    Trivigno, Silvia Maria Grazia; Vismara, Mauro; Canobbio, Ilaria; Rustichelli, Serena; Galvagni, Federico; Orlandini, Maurizio; Torti, Mauro; Guidetti, Gianni Francesco:

    The C-Type Lectin Receptor CD93 Regulates Platelet Activation and Surface Expression of the Protease Activated Receptor 4

    Image for article: The C-Type Lectin Receptor CD93 Regulates Platelet Activation and Surface Expression of the Protease Activated Receptor 4
    Supplementary Material (PDF)

    • Stroke, Systemic or Venous Thromboembolism

  • 135
    Grymonprez, Maxim; Petrovic, Mirko; De Backer, Tine L.; Steurbaut, Stephane; Lahousse, Lies:

    The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

    Image for article: The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
    Open Access
    Supplementary Material (PDF)

    • Invited Editorial Focus

  • 149
    Corica, Bernadette; Romiti, Giulio Francesco; Proietti, Marco:

    NOACs in Atrial Fibrillation Patients with Polypharmacy

    Image for article: NOACs in Atrial Fibrillation Patients with Polypharmacy

    • Stroke, Systemic or Venous Thromboembolism

  • 152
    Yoon, Dongwon; Jeong, Han Eol; Choi, Songhwa; Shin, Ju-Young; Bang, Soo-Mee:

    Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

    Image for article: Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study
    Open Access
    Supplementary Material (PDF)

    • Invited Editorial Focus

  • 163
    Germini, Federico; Chan, Noel C.:

    Patterns and Persistence of Anticoagulant Use in the Treatment of Venous Thromboembolism: Insights from South Korea

    • Atherosclerosis and Ischaemic Disease

  • 166
    He, Hao-ming; Chen, Yi-nong; Zeng, Ji-lang; Zheng, Shu-wen; Zhu, Long-yang; Wang, Zhe; Jiao, Si-qi; Yang, Fu-rong; Sun, Yi-hong:

    The Prognostic Value of the Age–D-Dimer–Albumin Score in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

    Image for article: The Prognostic Value of the Age–D-Dimer–Albumin Score in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Supplementary Material (PDF)

    • Letter to the Editor

  • 177
    Speed, Victoria; Clapham, Rachel; Bartoli-Abdou, John; Stirling, Katherine; Akor, Frances; Collings, Victoria; Patel, Rachna; Byrne, Rosalind; Arya, Roopen; Patel, Jignesh P.:

    Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg—Experience from Four UK Centers